
Findings presented at 50th Annual Meeting of ASCO show aromatase inhibitor effective for premenopausal women when combined with ovarian function suppression.

Findings presented at 50th Annual Meeting of ASCO show aromatase inhibitor effective for premenopausal women when combined with ovarian function suppression.

Results from 2 large, long-term clinical trials show benefits of extended-duration treatment with tamoxifen, resulting in an update to treatment guidelines.


Patients with HIV who smoke may be at even greater risk of developing smoking-related cancers.

Donna M. Smith, PharmD, director of clinical affairs at Avella Specialty Pharmacy discusses developments in the treatment of lung cancer that specialty pharmacies need to be aware of.

Emerging therapies and the role of specialty pharmacies in the treatment of non-small cell lung cancer were discussed during a continuing education session at the annual Armada summit.




Gazyva is a novel anti-CD20 monoclonal antibody approved, in combination with chlorambucil, for the treatment of previously untreated chronic lymphocytic leukemia patients.

Clinical trial results show that several new combination therapies offer great promise for the treatment of challenging neuroendocrine tumors in the gastrointestinal area.

With cancer ranking third among disease states in specialty spending, there is a growing emphasis on programs that focus on cost management and patient adherence to complex medication regimens.

Assessment, interventions, and outcomes information is vital to specialty pharmacy stakeholders.

The complexities of cancer and the ever-changing medication regimens employed in its treatment call for the specialized competencies of oncology-focused pharmacies. High-touch care and oncology expertise can improve outcomes.

Oncology nurses help improve patient outcomes through their dedication and expertise.


Research suggests salaried physicians practice in the same manner as those reimbursed by fee-for-service methodology.

Primary androgen-deprivation therapy appears not to be an effective treatment for men with clinically localized prostate cancer.

Service to dispense oral oncolytics to patients shows positive results, doctors say.

An increase in the number of available anti-cancer drugs will also help lead to more people surviving the disease than ever before.

Using a very high sensitivity assay analyzing changes in levels of MPO and troponin I before, and 3 months after starting a chemotherapy regimen, investigators were able to predict 46.5% of cases of chemotherapy-associated cardiotoxicity before they occurred.

Deaths from chronic hepatitis C virus infection in the United States are grossly underreported, the results of a new study indicate.

Case studies involving hot flashes and malaria prophylaxis.

Women who take aspirin regularly may be at a reduced risk for ovarian cancer, the results of a new meta-analysis suggest.

Rounding doses of ipilimumab to the nearest 50 mg resulted in significant cost savings for institutions, a new study found.

Scientists are using monoclonal antibodies to help the body fight off tumors in the same way that the body fights off infections. Monoclonal antibodies that target the interaction of programmed-death receptor-1 (PD-1) on T cells and its ligand (PD-L1) on tumor cells. Merck's MK-3475 prevents the interaction of PD-1 and PD-L1, thereby inhibiting a mechanism by which some tumors avoid immune detection.

Men who continue to smoke after being diagnosed with cancer are significantly more likely to die than those who quit, according to a recent study conducted in China.

The American Journal of Managed Care presents exclusive videos from the 2013 Patient-Centered Oncology Care: Real-World Perspectives conference.


Investigators strengthened the results of a 2012 trial with a long-term follow-up of an important phase III trial evaluating a bortezomib-based regimen versus a vincristine-based regimen.